Literature DB >> 9622397

Alcohol-related problems in Taiwan with particular emphasis on alcoholic liver diseases.

J D Liu1, K W Leung, C K Wang, L Y Liao, C S Wang, P H Chen, C C Chen, E K Yeh.   

Abstract

Socioeconomic development has led to a progressive increase of alcohol consumption in Taiwan, with an accompanying increase in alcohol-related psychiatric problems, traffic accidents, and liver disease. The prevalent rates of alcohol dependence for Han Chinese and Fomosan aborigines were 0.1% and 1%, respectively in 1950. The rate of alcohol dependence increased to 23% for aborigines in 1995. The number of cases of death and serious injuries due to alcohol-related traffic accident has decreased, and the number of fatalities resulting from these accidents has decreased from third to eighth since the inception of a program of random traffic stops with alcohol breath test in 1997. Alcohol liver disease (ALD) was defined as daily alcohol consumption of 60 g, for a duration of longer than 5 years. We classified ALD patients into two groups: (1) those whose average daily consumption of alcohol exceeded 120 g for a duration longer than 15 years (group A); and (2) all other patients (group B). The case records of 33 cases of biopsy-confirmed ALD were obtained for study. The average of daily alcohol consumption in these cases was 160 g. All but one of these patients were male, age ranged from 26 to 69 years, with an average of 43.1. Clinically, ill-defined gastrointestinal symptoms were the most common presentation (61%), and hepatomegaly was the main physical sign (73%). The average mean corpuscular volume values of ALD and non-ALD patients were 102.3 +/- 10.94 and 94.5 +/- 8.1, respectively (p < 0.01). The mean corpuscular volume values of group A and group B were 102.9 +/- 9.7 vs. 96.5 +/- 9.11 (p < 0.05). Result from serum SGOT/SGPT and gamma-glutamyltransferase/alkaline phosphatase for ALD and non-ALD revealed statistically significant differences between these groups. Using the avidin-biotin complex technique, tissue IgA deposition for ALD patients was found to be different from that of non-ALD patients. Ten of 13 ALD patients vs. 2 of 13 non-ALD patients had continuous-form IgA deposition. Histologically, 45.5% of ALD patients had alcoholic cirrhosis, whereas alcoholic hepatitis was present in only 9.1% of patients. Overall, 88% of cases showed various severity of fatty metamorphosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622397     DOI: 10.1111/acer.1998.22.s3_part1.164s

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  6 in total

Review 1.  Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?

Authors:  Alex Boye; Yu-Hong Zou; Yan Yang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Pathogenesis of alcoholic liver disease: the role of nuclear receptors.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2010-05

3.  Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma.

Authors:  Yun-Hsuan Lee; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Yi-You Chiou; Han-Chieh Lin; Teh-Ia Huo; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2012-05-17       Impact factor: 6.047

Review 4.  Mechanisms of intrahepatic triglyceride accumulation.

Authors:  Claudia Ress; Susanne Kaser
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan.

Authors:  Shu-Fen Liao; Hwai-I Yang; Mei-Hsuan Lee; Chien-Jen Chen; Wen-Chung Lee
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

Review 6.  Beneficial effects of naringenin in liver diseases: Molecular mechanisms.

Authors:  Erika Hernández-Aquino; Pablo Muriel
Journal:  World J Gastroenterol       Date:  2018-04-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.